Lipitor, Atorvastatin
Lipitor, Atorvastatin Newswire (Page 9)

Lipitor, Atorvastatin Newswire (Page 9)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 9)

Results 161 - 180 of 953 in Lipitor, Atorvastatin (generic)

  1. UPDATE 1-New cholesterol drugs won't be budget busters -Express ScriptsRead the original story

    Sep 30, 2015 | Reuters

    Express Scripts Holding Co said on Wednesday two costly new cholesterol fighters will not be "budget busters" for its clients and that most prescriptions for the potent drugs have been rejected because patients did not meet required medical criteria. "We're seeing a lot of patients who either don't qualify or their physicians are not providing information," said Everett Neville, a vice president of Express Scripts, the largest pharmacy benefit manager in the United States.

    Comment?

  2. Short Interest in Pfizer Expands By 32.2%Read the original story

    Sep 30, 2015 | AmericanBankingNews.com

    Pfizer was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 73,588,993 shares, an increase of 32.2% from the August 31st total of 55,656,061 shares, Market Beat.com reports.

    Comment?

  3. More calcium doesn't reduce fracture risks or boost bone health: studiesRead the original story w/Photo

    Sep 29, 2015 | Globe and Mail

    Bottles of Atorvastatin Calcium tablets, a generic form of Lipitor, are shown in an undated photo. Bottles of Atorvastatin Calcium tablets, a generic form of Lipitor, are shown in an undated photo.

    Comment?

  4. AbbVie's VIEKIRAXA (ombitasvir/paritaprevir/ritonavir tablets)...Read the original story

    Sep 27, 2015 | Sys-Con Media

    "Today's approval represents an important step forward for the treatment of Japanese patients, a population with specific needs based on patient and viral characteristics," said Jean-Michel Pawlotsky, MD, PhD, professor of medicine at the University of Paris-Est, . "VIEKIRAX is a valuable new addition to a number of treatments that are changing the face of hepatitis C, making it possible to achieve high virologic cure rates, even in patients whose disease has progressed to compensated liver cirrhosis."

    Comment?

  5. Pfizer Earns "Outperform" Rating from BMO Capital MarketsRead the original story

    Sep 25, 2015 | AmericanBankingNews.com

    's stock had its "outperform" rating reaffirmed by BMO Capital Markets in a research report issued on Friday, Market Beat Ratings reports. They presently have a $41.00 target price on the biopharmaceutical company's stock.

    Comment?

  6. Indoco Remedies Limited (INDOCO) - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story w/Photo

    Sep 25, 2015 | PR-inside.com

    Indoco Remedies Limited is a pharmaceutical company. The company manufactures and markets formulations and active pharmaceutical ingredients.

    Comment?

  7. Pfizer Inc. to Issue $0.28 Quarterly DividendRead the original story

    Sep 25, 2015 | AmericanBankingNews.com

    Pfizer declared a quarterly dividend on Friday, September 25th, MarketBeat reports. Shareholders of record on Friday, November 6th will be paid a dividend of 0.28 per share by the biopharmaceutical company on Tuesday, December 1st.

    Comment?

  8. Pfizer Given Consensus Rating of "Buy" by BrokeragesRead the original story

    Sep 23, 2015 | AmericanBankingNews.com

    Pfizer has earned a consensus rating of "Buy" from the thirteen research firms that are presently covering the company, AnalystRatings.Net reports . One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company.

    Comment?

  9. Pfizer Sees Significant Growth in Short InterestRead the original story

    Sep 23, 2015 | AmericanBankingNews.com

    Pfizer was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 55,656,061 shares, a growth of 22.1% from the August 14th total of 45,590,499 shares, Marketbeat.com reports.

    Comment?

  10. Pfizer says it could be leader in cancer with many new drugsRead the original story w/Photo

    Sep 22, 2015 | The Tribune

    Drug giant Pfizer is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in one of the hottest, and most lucrative, areas of medicine. A decade ago, the world's second-biggest drugmaker by revenue wasn't even a player in cancer medicine.

    Comment?

  11. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term...Read the original story

    Sep 22, 2015 | CiteULike

    Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Following acute coronary syndrome , the risk for future cardiovascular events is high and is related to levels of low-density lipoprotein cholesterol even within the setting of intensive statin treatment.

    Comment?

  12. Oxford Pharmascience Group Plc Stock Rating Reaffirmed by N+1 SingerRead the original story

    Sep 22, 2015 | AmericanBankingNews.com

    's stock had its "corporate" rating reaffirmed by research analysts at N+1 Singer in a report released on Tuesday, ARN reports. Oxford Pharmascience Group Plc traded down 1.75% during trading on Tuesday, hitting GBX 7.00.

    Comment?

  13. Doubts Rise About Surge In Statin Prescriptions For Oldest AmericansRead the original story w/Photo

    Sep 21, 2015 | News 88.9 KNPR

    Inexpensive statin drugs are given to millions of people to reduce cholesterol, even many who don't show signs of heart disease. A recent study has found that seniors with no history of heart trouble are now nearly four times more likely - from 9 percent to 34 percent - to get those drugs than they were in 1999.

    Comment?

  14. Surge In Statin Use Among Very Elderly Without Heart Trouble Raises DoubtsRead the original story w/Photo

    Sep 21, 2015 | KRMG-AM Tulsa

    Inexpensive statin drugs are given to millions of people to reduce cholesterol, even many who do not show signs of heart disease. But a recent study has found that seniors with no history of heart trouble are now four times more likely to get those drugs than they were in 1999.

    Comment?

  15. 2 cholesterol drugs pricey, promisingRead the original story w/Photo

    Sep 20, 2015 | The Columbus Dispatch

    Almost three decades after the advent of statins, two new, powerful cholesterol drugs gained approval by the U.S. Food and Drug Administration. emia," which drives LDL, or "bad," cholesterol levels sky high and can lead to heart attacks and deaths at a young age.

    Comment?

  16. Dr. Roach: High LDL needs treatment, even with low calcium scoreRead the original story w/Photo

    Sep 18, 2015 | Lubbock Avalanche-Journal

    Dear Dr. Roach: I'm writing to request a second opinion regarding my cholesterol situation. After 20-plus years on statins, I have become concerned about perceived muscle fatigue.

    Comment?

  17. Effect of High-Dose Statin Therapy on Drug-Eluting Stent Strut Coverage [Original Research]Read the original story

    Sep 10, 2015 | Circulation

    From the Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea ; and Cardiovascular Research Institute and Severance Biomedical Science Institute , Yonsei University College of Medicine, Seoul, Korea. Correspondence to Myeong-Ki Hong, MD, PhD, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.

    Comment?

  18. New Cholesterol Drugs Too Pricey, Group SaysRead the original story w/Photo

    Sep 9, 2015 | MSNBC

    An independent non-profit organization that evaluates clinical and cost effectiveness of new medicines said announced prices for a just-approved class of potent cholesterol lowering drugs were far too high, according to a draft report released on Tuesday. Praluent, made by Regeneron Pharmaceuticals and Sanofi will cost $14,600 for a year of treatment.

    Comment?

  19. Amgen's Acquisition Of Dezima Pharma And CETP Drug Like Pfizer's '03...Read the original story

    Sep 16, 2015 | BioSpace

    In 2003, Pfizer PFE +0.00% purchased Esperion Therapeutics for $1.3 billion for access to Esperion's experimental medicine, ETC-216, an early stage synthetic, biological drug that mimicked the beneficial effects of HDL and in so doing potentially could reverse atherosclerosis. At the time the deal was viewed positively by industry analysts as it put Pfizer in a position to have three blockbuster medicines in its cardiovascular pipeline: Lipitor, ETC-216, and the CETP inhibitor, torcetrapib.

    Comment?

  20. Why Americans are falling out of love with one of their favorite fruitsRead the original story w/Photo

    Sep 15, 2015 | Salt Lake Tribune

    Washington a I was looking through USDA data, as I do from time to time, mindlessly scrolling through numbers and names of foods, when a column in a spreadsheet gave me pause. I had opened the government agency's most recent estimates of fruit consumption and realized that grapefruits, for some reason, have become terribly unpopular.

    Comment?